1. ATIM-30. HOW TO MONITOR IMMUNOGENIC CELL DEATH IN PATIENTS WITH GLIOBLASTOMA. (5th November 2018) Authors: Van Gool, Stefaan; Feyen, Oliver; Makalowski, Jennifer; Neinhuis, Andrea; Schirrmacher, Volker; Stuecker, Wilfried Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. (2014) Authors: Schirrmacher, Volker; Fournier, Philippe; Schlag, Peter Journal: Expert review of vaccines Issue: Volume 13:Number 1(2014) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. (January 2014) Authors: Schirrmacher, Volker; Fournier, Philippe; Schlag, Peter Journal: Expert review of vaccines Issue: Volume 13:Number 1(2014) Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN. (4th December 2020) Authors: Van Gool, Stefaan; Makalowski, Jennifer; Bonner, Erin R; Feyen, Oliver; Domogalla, Matthias; Prix, Lothar; Schirrmacher, Volker; Nazarian, Javad; Stücker, Wilfried Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 3 Page Start: iii294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. IMMU-03. Synergy between TMZ and individualized multimodal immunotherapy to improve Overall Survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. (3rd June 2022) Authors: Van Gool, Stefaan; Makalowski, Jennifer; Bitar, Michael; Van de Vliet, Peter; Schirrmacher, Volker; Stuecker, Wilfried Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 1 Page Start: i81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. IMMU-07. IMMUNOGENIC CELL DEATH DURING MAINTENANCE CHEMOTHERAPY AND SUBSEQUENT MULTIMODAL IMMUNOTHERAPY FOR GBM. Issue 2 (22nd June 2018) Authors: Van Gool, Stefaan; Makalowski, Jennifer; Schirrmacher, Volker; Stuecker, Wilfried Journal: Neuro-oncology Issue: Volume 20:Issue 2(2018)supplement 2 Page Start: i99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. IMMU-25. SYNERGY BETWEEN TMZ AND INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY TO IMPROVE OS OF IDH1 WILD TYPE MGMT PROMOTOR UNMETHYLATED GBM PATIENTS. (12th November 2021) Authors: Van Gool, Stefaan; Makalowski, Jennifer; Schirrmacher, Volker; Stuecker, Wilfried Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report. (August 2015) Authors: Schirrmacher, Volker; Stücker, Wilfried; Lulei, Maria; Bihari, Akos-Sigmund; Sprenger, Tobias Journal: Immunotherapy Issue: Volume 7:Number 8(2015:Aug.) Page Start: 855 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Position paper: new insights into the immunobiology and dynamics of tumor–host interactions require adaptations of clinical studies. Issue 8 (2nd August 2020) Authors: Sprenger, Tobias; Schirrmacher, Volker; Stücker, Wilfried; van Gool, Stefaan W Journal: Expert review of anticancer therapy Issue: Volume 20:Issue 8(2020) Page Start: 639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Tumor Antigen-Dependent and Tumor Antigen-Independent Activation of Antitumor Activity in T Cells by a Bispecific Antibody-Modified Tumor Vaccine. (1st March 2011) Authors: Fournier, Philippe; Schirrmacher, Volker Other Names: Mannering Stuart Academic Editor. Journal: Clinical & developmental immunology Issue: Volume 2010(2010) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗